Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: A good local response but no good survival due to radiation pneumonitis

Lung Cancer

Volumn 40, Issue 1, 2003, Pages 79-84

  Onishi, Hiroshi ^a   Kuriyama, Kengo ^a   Yamaguchi, Motoshi ^a   Komiyama, Takafumi ^a   Tanaka, Shiho ^a   Araki, Tsutomu ^a   Nishikawa, Keiichi ^a   Ishihara, Hiroshi ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Chemoradiation pneumonitis; Concurrent chemoradiation; Non small cell lung cancer; Survival rate; Two dimensional radiotherapy; Weekly docetaxel

Indexed keywords

DOCETAXEL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; FEMALE; GASTROINTESTINAL TOXICITY; HAIR LOSS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; TREATMENT OUTCOME;

EID: 0037378463     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00532-9     Document Type: Article

References (19)

1. Dillman R.O., Seagren S.L., Propert K., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N. Engl. J. Med. 323:1990;940-945.
2. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small cell lung cancer: seven-year follow up of cancer and leukemia group B (CALGB) 8433 trial. J. Natl. Cancer Inst. 88:1996;1210-1215.
3. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 17:1999;2692-2699.
4. Bissery M.C., Nohynek G., Sanderink G., et al. Docetaxel (Taxotere): a review of preclinical and clinical experience: part I: preclinical experience. Anticancer Drugs. 6:1995;339-355.
5. Diaz J.F., Andreu J.M. Assembly of purified GDP-tublin into microtubles induced by RP 56976 and paclitaxel: reversibility, ligand stoichimetry and competition. Biochemistry. 32:1993;2747-2755.
6. Lavelle F., Bissery M.C., Combeau C., et al. Preclinical evaluation of docetaxel (Taxotere). Semin. Oncol. 22:1995;3-16.
7. Koukourakis M.I., Kourousis C., Kamilaki M., et al. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur. J. Cancer. 34:1998;838-844.
8. Koukourakis M.I., Bahlitzanakis N., Froudarakis M., et al. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small cell lung cancer. British J. Cancer. 80:1999;1792-1796.
9. Mauer A.M., Masters G.A., Haraf D.J., et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J. Clin. Oncol. 16:1998;159-164.
10. Aamdal S., Lauvvang G., Owre K., et al. A phase I/II study of docetaxel (Taxotere) combined with concurrent radiation therapy in locally advanced non-small cell lung cancer (NSCLC) (abstr). J. Int. Assoc. Study Lung Cancer. 29:(Suppl. 1):2000;100.
11. Hainsworth J.D., Burris H.A., Erland J.B., et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol. 16:1998;2164-2168.
12. Luck H.J., Donne S., Glaubitz M., et al. Phase I study of weekly docetaxel (Taxotere) in heavily pretreated breast cancer patients (abstr). Eur. J. Cancer. 33:(Suppl. 8):1997;S158.
13. Lueffler T.M., Freund W., Hausamen T.U. Activity of weekly Taxotere (TXT) in patients with metastatic breast cancer (abstr). Proc. Am. Soc. Clin. Oncol. 17:1998;113a.
14. Fossella F.V. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. Semin. Oncol. 26:(Suppl. 16):1999;17-23.
15. Hainsworth J.D., Burris H.A., Litchy S., et al. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung cancer: a Minnie Pearl Cancer Research Network phase II trial. Cancer. 89:2000;328-333.
16. Greco F.A. Docetaxel (Taxotere) administered in weekly schedules. Semin. Oncol. 3:(Suppl. 11):1999;28-31.
17. Koukourakis M.I., Romanidis K., Froudarakis M., et al. Concorrent administration of docetaxel and stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br. J. Cancer. 87:2002;385-392.
18. Wong J.W., Sharpe M.B., Jasffray D.A., et al. The use of active breathing control (ABC) to reduce margin for breathing motion. Int. J. Radiat. Biol. Phys. 44:1999;911-919.
19. Rosenzweig K.E., Hanley J., Mah D., et al. The deep inspiration breath-hold technique in the treatment of inoperable non-small cell lung cancer. Int. J. Radiat. Biol. Phys. 48:2000;81-87.